PepsiCo under pressure as weight-loss drug boom challenges growth goals
Investors are looking for signs of a turnaround in North America as rising costs, weaker snack demand and GLP-1 drugs weigh on performance
Reuters3 min read
Share

File picture of bottles of Pepsi used for illustrative purpose. Analysts surveyed by LSEG expect PepsiCo to report third-quarter revenue of $24.96 billion, up 4.3% from a year earlier, while adjusted earnings per share are forecast to increase 0.21% to about $2.29. Reuters
Add Emirates 24|7 to your Google News
Text Size:
